The Impact of the GOLD 2023 on Clinical Treatment in Northeast China.

Abstract

Chronic obstructive pulmonary disease (COPD) is distinguished by a gradual decline in airflow, accompanied by a growing load of symptoms and economic consequences. 1 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines serve as the fundamental framework for directing the diagnosis, treatment, and management of COPD. The most recent significant revision, GOLD 2023, not only modified the disease assessment tool for categorization purposes but also revised the medication recommendations for each group. However, the ramifications of those alterations on the Chinese COPD population remain unexplored and warrant further investigation.